Clin Cancer Res. 2008 May 15;14(10):2988-93. doi: 10.1158/1078-0432.CCR-07-4723.
Wittner B.S., Sgroi D.C., Ryan P.D., Bruinsma T.J., Glas A.M., Male A., Dahiya S., Habin K., Bernards R., Haber D.A., Van’t Veer L.J., Ramaswamy S.
The MammaPrint assay was originally designed to identify younger breast cancer patients at low risk for distant metastasis, who might consequently be spared systemic treatment. We show here that the same signature has a very high NPV for distant recurrence after adjuvant treatment in older breast cancer patients.